We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Compugen Ltd | NASDAQ:CGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0999 | 4.73% | 2.2099 | 2.11 | 2.20 | 2.17 | 2.09 | 2.17 | 178,293 | 23:56:35 |
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial Officer of Compugen, will present a corporate overview and update at the Oppenheimer 26th Annual Healthcare Conference in New York, on Tuesday, December 8, 2015.
About Compugen
Compugen is a leading drug discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The Company’s current pipeline primary focus is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen’s business model is based on selectively entering into collaborations for its novel targets and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Tel Aviv, Israel, with R&D facilities in Tel Aviv and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company’s novel target candidates. For additional information, please visit Compugen's corporate website at www.cgen.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151124005382/en/
Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media Liaisontsipih@cgen.com
1 Year Compugen Chart |
1 Month Compugen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions